CD80 and neoplasm: Conversely, the upregulation of certain ligand–receptor interactions, such as ADORA2A–ENTPD1, CLEC2D–KLRB1, CD80–CTLA4, and CD86-CTLA4, is indicative of inhibitory regulation of T and B cells (43–46), implying a detrimental effect on tumor immunity.